RZLT - Rezolute, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1120
-0.0230 (-17.04%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close0.1350
Open0.1400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1120 - 0.1400
52 Week Range0.0800 - 0.4960
Volume15,100
Avg. Volume31,321
Market Cap32.852M
Beta (5Y Monthly)3.87
PE Ratio (TTM)N/A
EPS (TTM)-0.2440
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.47
  • GlobeNewswire

    Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes

    AB101 was administered subcutaneously in three ascending dosing cohorts in patients with type 1 diabetes, which resulted in slow onset and sustained insulin levels and activity for more than seven days. Consequently, the Company believes that additional formulation development is required before advancing the program further in the clinic. This single ascending dose study, AB101-01, was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AB101, in subjects with type 1 diabetes who were on background continuous, subcutaneous insulin infusion.

  • GlobeNewswire

    Rezolute Management to Present at 2020 Biotech Showcase Conference

    REDWOOD CITY, Calif., Dec. 02, 2019 -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2020 Biotech Showcase.

  • GlobeNewswire

    Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors

    Rezolute, Inc. (“Rezolute” or the “Company”) (RZLT), a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced today the appointment of Gil Labrucherie to its Board of Directors (“Board”) where he will serve as Chairman of the Audit Committee. Mr. Labrucherie is currently the Chief Operating Officer and Chief Financial Officer of Nektar Therapeutics.

  • GlobeNewswire

    Rezolute Management to Present at 2019 BIO Investor Forum Conference

    REDWOOD CITY, Calif., Oct. 11, 2019 -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 BIO Investor Forum.

  • GlobeNewswire

    Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference

    REDWOOD CITY, Calif., Aug. 05, 2019 -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 Canaccord Genuity.

  • GlobeNewswire

    Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option

    Rezolute, Inc. (“Rezolute”) (RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative therapies targeting metabolic and orphan diseases, announced today that Handok, Inc. (“Handok”) and Genexine, Inc. (“Genexine”), exercised their combined full $20 million option to purchase shares of Rezolute common stock, increasing their combined aggregate investment in Rezolute to $45 million.  Each share of common stock was priced at $0.29 in this offering. “We are very appreciative of the continued support of Genexine and Handok.

  • PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers

    NEW YORK , April 18, 2019 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...